Issue |
BIO Web Conf.
Volume 174, 2025
2025 7th International Conference on Biotechnology and Biomedicine (ICBB 2025)
|
|
---|---|---|
Article Number | 02024 | |
Number of page(s) | 7 | |
Section | Innovations in Therapeutics and Disease Mechanisms | |
DOI | https://doi.org/10.1051/bioconf/202517402024 | |
Published online | 12 May 2025 |
Development of a Cell line Classifier for Precision Subtyping of Triple-Negative Breast Cancer
State Key Laboratory of Digital Medical Engineering, School of Biological Science & Medical Engineering, Southeast University, Nanjing 210096, China
* Corresponding author: haohuang@seu.edu.cn
Triple-negative breast cancer (TNBC) exhibits marked clinical diversity and an absence of established targeted therapies, largely driven by heterogeneous tumor phenotypes and transcriptional profiles across subtypes. This biological variability complicates therapeutic strategies and underscores the unmet need for refined molecular classification systems. While molecular insights into TNBC pathogenesis have expanded, clinical applications remain constrained by insufficiently validated stratification tools. To address this gap, we developed an RNA-seq based classifier specifically optimized for TNBC cell lines, designed to enable refined subtype stratification and mechanistic exploration of molecular drivers.
© The Authors, published by EDP Sciences, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.